ALPHARX INC
10SB12G/A, EX-27.1, 2000-09-19
PHARMACEUTICAL PREPARATIONS
Previous: ALPHARX INC, 10SB12G/A, 2000-09-19
Next: NEW D&B CORP, S-8, 2000-09-19



<TABLE> <S> <C>


<ARTICLE>                     5


<S>                             <C>                         <C>                          <C>
<PERIOD-TYPE>                   12-MOS                      12-MOS                       9-MOS
<FISCAL-YEAR-END>                       SEP-30-1998                 SEP-30-1999                  SEP-30-2000
<PERIOD-END>                            SEP-30-1998                 SEP-30-1999                  JUN-30-2000
<CASH>                                      128,510                       1,562                       54,726
<SECURITIES>                                      0                      46,408                       46,408
<RECEIVABLES>                                 1,621                           0                          313
<ALLOWANCES>                                      0                           0                            0
<INVENTORY>                                       0                           0                            0
<CURRENT-ASSETS>                            130,131                       1,562                       55,039
<PP&E>                                        7,301                       3,235                       48,056
<DEPRECIATION>                                2,460                       6,526                       11,816
<TOTAL-ASSETS>                              137,432                      51,205                      149,503
<CURRENT-LIABILITIES>                        36,136                      19,026                        7,612
<BONDS>                                           0                           0                            0
                             0                           0                            0
                                       0                           0                            0
<COMMON>                                      4,083                       4,228                        4,909
<OTHER-SE>                                  101,296                      32,179                      141,891
<TOTAL-LIABILITY-AND-EQUITY>                137,432                      51,205                      149,503
<SALES>                                           0                           0                            0
<TOTAL-REVENUES>                             11,323                       3,725                        1,411
<CGS>                                             0                           0                            0
<TOTAL-COSTS>                                     0                           0                            0
<OTHER-EXPENSES>                           (225,055)                   (800,842)                    (200,924)
<LOSS-PROVISION>                                  0                           0                            0
<INTEREST-EXPENSE>                                0                           0                            0
<INCOME-PRETAX>                            (213,732)                   (797,117)                    (199,513)
<INCOME-TAX>                                      0                           0                            0
<INCOME-CONTINUING>                          11,323                       3,725                        1,411
<DISCONTINUED>                                    0                           0                            0
<EXTRAORDINARY>                                   0                           0                            0
<CHANGES>                                         0                           0                            0
<NET-INCOME>                               (213,732)                   (797,117)                    (199,513)
<EPS-BASIC>                                   (.095)                      (.188)                       (.040)
<EPS-DILUTED>                                 (.095)                      (.188)                       (.040)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission